Academic Journal
Accurate Quantification of Mutant and Wild-Type polyQ Proteins Using Simple Western Capillary Immunoassays.
| Τίτλος: | Accurate Quantification of Mutant and Wild-Type polyQ Proteins Using Simple Western Capillary Immunoassays. |
|---|---|
| Συγγραφείς: | Röttgering B; VICO Therapeutics B.V., J.H. Oortweg 21, 2333 CH, Leiden, The Netherlands.; Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands., Testerink J; VICO Therapeutics B.V., J.H. Oortweg 21, 2333 CH, Leiden, The Netherlands., Weij R; VICO Therapeutics B.V., J.H. Oortweg 21, 2333 CH, Leiden, The Netherlands., Beekman C; VICO Therapeutics B.V., J.H. Oortweg 21, 2333 CH, Leiden, The Netherlands., Datson N; VICO Therapeutics B.V., J.H. Oortweg 21, 2333 CH, Leiden, The Netherlands. nicole.datson@vicotx.com. |
| Πηγή: | Molecular neurobiology [Mol Neurobiol] 2025 Oct; Vol. 62 (10), pp. 12768-12790. Date of Electronic Publication: 2025 May 31. |
| Τύπος έκδοσης: | Journal Article |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Humana Press Country of Publication: United States NLM ID: 8900963 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1559-1182 (Electronic) Linking ISSN: 08937648 NLM ISO Abbreviation: Mol Neurobiol Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Clifton, NJ : Humana Press, c1987- |
| Ιατρικοί όροι (MeSH): | Peptides*/analysis , Peptides*/genetics , Peptides*/metabolism , Mutation*/genetics , Mutant Proteins*/analysis , Mutant Proteins*/metabolism , Blotting, Western*/methods, Immunoassay/methods ; Humans ; Huntingtin Protein ; Animals |
| Περίληψη: | Polyglutamine (polyQ) diseases are monogenic fatal neurodegenerative disorders caused by a CAG repeat expansion that is translated into a toxic polyQ tract. There are nine polyQ diseases: Huntington's disease (HD), spinocerebellar ataxias 1, 2, 3, 6, 7 and 17 (SCA1, 2, 3, 6, 7, 17), dentatorubral-pallidoluysian atrophy (DRPLA) and spinal and bulbar muscular atrophy (SBMA). Although no disease-modifying therapies are available, lowering levels of the causative mutant polyQ protein is a promising potential treatment. Preclinically, the efficacy of polyQ protein-lowering compounds is often assessed using time-consuming Western blots (WB), which can produce variable results. Therefore, to improve throughput and accuracy of polyQ protein level quantification, Simple Western (SW) capillary immunoassays were developed. A panel of antibodies was screened for reactivity to the polyQ proteins on SW. The most promising antibodies were selected for further assay development. This resulted in optimised SW immunoassays for huntingtin (HTT), ataxin 1, 2 and 3 (ATXN1, 2, 3), atrophin 1 (ATN1) and androgen receptor (AR). Additionally, size-separation of the wild-type and polyQ-expanded mutant protein isoforms on SW was shown for ATXN1, ATXN3 and ATN1, allowing for their separate quantification. To facilitate size-separation of the larger HTT protein (≥ 348 kDa), a novel caspase 3-based assay was developed to generate N-terminal wild-type and mutant HTT fragments that could be separately quantified on SW in contrast to full-length HTT. In conclusion, SW capillary immunoassays were developed for polyQ proteins to improve preclinical research and aid the development of polyQ-lowering therapies for polyQ diseases. (© 2025. The Author(s).) |
| Competing Interests: | Declarations. Ethics Approval: Not applicable. Consent to Participate: Not applicable. Consent for Publication: Not applicable. Competing Interests: Financial interest: All authors are employed and paid by VICO Therapeutics B.V. and hold employee stock options. |
| References: | Neuron. 1997 Aug;19(2):333-44. (PMID: 9292723) Hum Mol Genet. 2002 Nov 1;11(23):2905-17. (PMID: 12393802) Mov Disord. 2023 Aug;38(8):1428-1442. (PMID: 37278528) Proc Natl Acad Sci U S A. 2013 Feb 5;110(6):2366-70. (PMID: 23341618) Annu Rev Pathol. 2019 Jan 24;14:1-27. (PMID: 30089230) Sci Adv. 2023 Mar 17;9(11):eade2175. (PMID: 36921044) J Biol Chem. 1999 Mar 26;274(13):8730-6. (PMID: 10085113) Int Rev Neurobiol. 2011;98:325-72. (PMID: 21907094) N Engl J Med. 2023 Dec 7;389(23):2203-2205. (PMID: 38055260) FEBS J. 2010 Dec;277(23):4873-87. (PMID: 20977674) Mov Disord. 2021 Nov;36(11):2464-2467. (PMID: 34783387) J Vis Exp. 2018 Feb 27;(132):. (PMID: 29553509) Int J Mol Sci. 2024 Jun 20;25(12):. (PMID: 38928495) Electrophoresis. 2009 Jun;30(11):1845-55. (PMID: 19517440) J Transl Med. 2015 Jun 06;13:182. (PMID: 26048678) Biotechnol Genet Eng Rev. 2013;29:73-109. (PMID: 24568254) Molecules. 2018 Oct 08;23(10):. (PMID: 30297632) Methods Protoc. 2023 Apr 20;6(2):. (PMID: 37104025) Br J Clin Pharmacol. 2024 Dec;90(12):3242-3251. (PMID: 39155237) Neurology. 1995 Jan;45(1):143-9. (PMID: 7824105) J Immunol Methods. 2003 Mar 1;274(1-2):1-15. (PMID: 12609528) J Pathol. 2008 Dec;216(4):387-93. (PMID: 18853439) Neurol Res Pract. 2019 Jul 03;1:22. (PMID: 33324888) Hum Mol Genet. 1998 Feb;7(2):171-6. (PMID: 9425223) Biochim Biophys Acta. 2013 May;1829(5):455-68. (PMID: 23403288) Neurobiol Dis. 2024 Apr;193:106456. (PMID: 38423193) Nature. 2008 Apr 10;452(7188):713-8. (PMID: 18337722) Mol Neurodegener. 2015 Apr 28;10:21. (PMID: 25928884) Genome Med. 2009 Aug 21;1(8):80. (PMID: 19725930) PLoS One. 2017 Feb 9;12(2):e0171127. (PMID: 28182673) Proc Natl Acad Sci U S A. 2009 Feb 10;106(6):1760-5. (PMID: 19181854) Annu Rev Neurosci. 2007;30:575-621. (PMID: 17417937) Cell. 1996 Nov 1;87(3):493-506. (PMID: 8898202) Database (Oxford). 2023 Aug 18;2023:. (PMID: 37599593) J Biol Chem. 2019 Jan 11;294(2):644-661. (PMID: 30455355) Cell Death Dis. 2024 Jun 14;15(6):415. (PMID: 38877004) Sci Rep. 2021 Jan 26;11(1):2184. (PMID: 33500497) MAbs. 2018 May/Jun;10(4):539-546. (PMID: 29485921) Nucleic Acids Res. 2011 Nov 1;39(20):8938-51. (PMID: 21795378) Elife. 2021 May 13;10:. (PMID: 33983118) PLoS Genet. 2010 Jul 08;6(7):e1001021. (PMID: 20628574) Curr Trends Neurol. 2011 Jan 1;5:65-78. (PMID: 22180703) Hum Mol Genet. 2005 May 15;14(10):1379-92. (PMID: 15829505) EMBO Mol Med. 2024 Mar;16(3):523-546. (PMID: 38374466) Brain. 2020 Feb 1;143(2):407-429. (PMID: 31738395) Electrophoresis. 2021 Feb;42(3):206-218. (PMID: 33185281) J Clin Invest. 2015 May;125(5):1979-86. (PMID: 25844897) Hum Mutat. 2002 Sep;20(3):233. (PMID: 12204002) Front Cell Neurosci. 2018 Sep 19;12:290. (PMID: 30283301) Mol Med. 2024 Mar 8;30(1):36. (PMID: 38459427) Mov Disord. 2022 Dec;37(12):2327-2335. (PMID: 36161673) Neurol Genet. 2017 May 15;3(3):e155. (PMID: 28534046) Neuron. 2015 Nov 18;88(4):667-77. (PMID: 26590344) J Biol Chem. 2003 Apr 11;278(15):13047-55. (PMID: 12464607) Anal Biochem. 2023 Aug 1;674:115198. (PMID: 37302777) Brain. 2006 Jun;129(Pt 6):1446-55. (PMID: 16621916) J Biol Chem. 2008 Apr 18;283(16):10745-52. (PMID: 18292091) J Biol Chem. 2000 Jun 30;275(26):19831-8. (PMID: 10770929) Hum Mol Genet. 1995 Jun;4(6):1001-5. (PMID: 7655453) J Neurol. 2021 Apr;268(4):1304-1315. (PMID: 33106888) Ann Neurol. 1996 Apr;39(4):500-6. (PMID: 8619528) Sci Signal. 2015 Apr 07;8(371):rs2. (PMID: 25852189) Anal Biochem. 2020 Mar 15;593:113608. (PMID: 32007473) Neurology. 1997 Nov;49(5):1238-43. (PMID: 9371900) ACS Chem Neurosci. 2018 Jun 20;9(6):1399-1408. (PMID: 29506378) Mov Disord. 2021 Nov;36(11):2675-2681. (PMID: 34397117) Eur J Hum Genet. 2015 Nov;23(11):1505-12. (PMID: 25735478) Nucleic Acids Res. 2014 Jun;42(11):6787-810. (PMID: 24848018) Nature. 2015 Feb 5;518(7537):27-9. (PMID: 25652980) Neurology. 2023 Jan 3;100(1):e84-e93. (PMID: 36180235) Adv Exp Med Biol. 2018;1049:219-231. (PMID: 29427105) J Biol Chem. 1998 Apr 10;273(15):9158-67. (PMID: 9535906) Biomed Res Int. 2019 Jan 21;2019:5214821. (PMID: 30800670) Int J Clin Exp Pathol. 2011 Apr;4(4):378-84. (PMID: 21577324) Nat Commun. 2019 Sep 19;10(1):4262. (PMID: 31537808) Neurotherapeutics. 2019 Oct;16(4):1050-1073. (PMID: 31435879) Neuroepidemiology. 2014;42(3):174-83. (PMID: 24603320) Int J Mol Sci. 2021 Apr 19;22(8):. (PMID: 33921915) Mol Ther Nucleic Acids. 2019 Sep 6;17:601-614. (PMID: 31394429) PLoS One. 2012;7(9):e44785. (PMID: 22970306) Trends Neurosci. 2001 Mar;24(3):182-8. (PMID: 11182459) ILAR J. 2007;48(4):356-73. (PMID: 17712222) Cell Death Dis. 2013 Aug 01;4:e752. (PMID: 23907466) Am J Med Genet B Neuropsychiatr Genet. 2010 Mar 5;153B(2):397-408. (PMID: 19548255) Neuroscientist. 2011 Oct;17(5):475-92. (PMID: 21311053) Am J Hum Genet. 2024 May 2;111(5):913-926. (PMID: 38626762) Sci Adv. 2021 Aug 20;7(34):. (PMID: 34417184) Brain Pathol. 2016 Nov;26(6):779-786. (PMID: 27529325) J Mol Biol. 2020 Dec 4;432(24):166699. (PMID: 33157084) |
| Contributed Indexing: | Keywords: Assay development; Capillary immunoassay; Huntington’s disease; Polyglutamine diseases; Protein quantification; Spinocerebellar ataxias |
| Substance Nomenclature: | 26700-71-0 (polyglutamine) 0 (Peptides) 0 (Mutant Proteins) 0 (Huntingtin Protein) |
| Entry Date(s): | Date Created: 20250531 Date Completed: 20250916 Latest Revision: 20250916 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC12433360 |
| DOI: | 10.1007/s12035-025-05089-9 |
| PMID: | 40450087 |
| Βάση Δεδομένων: | MEDLINE |
| FullText | Links: – Type: other Url: https://resolver.ebsco.com:443/public/rma-ftfapi/ejs/direct?AccessToken=47E299EC158358D47377&Show=Object Text: Availability: 0 CustomLinks: – Url: https://dx.doi.org/doi:10.1007/s12035-025-05089-9 Name: EDS - Springer Nature Journals (s7799221) Category: fullText Text: View record at Springer |
|---|---|
| Header | DbId: cmedm DbLabel: MEDLINE An: 40450087 AccessLevel: 3 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Accurate Quantification of Mutant and Wild-Type polyQ Proteins Using Simple Western Capillary Immunoassays. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Röttgering+B%22">Röttgering B</searchLink>; VICO Therapeutics B.V., J.H. Oortweg 21, 2333 CH, Leiden, The Netherlands.; Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Testerink+J%22">Testerink J</searchLink>; VICO Therapeutics B.V., J.H. Oortweg 21, 2333 CH, Leiden, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Weij+R%22">Weij R</searchLink>; VICO Therapeutics B.V., J.H. Oortweg 21, 2333 CH, Leiden, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Beekman+C%22">Beekman C</searchLink>; VICO Therapeutics B.V., J.H. Oortweg 21, 2333 CH, Leiden, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Datson+N%22">Datson N</searchLink>; VICO Therapeutics B.V., J.H. Oortweg 21, 2333 CH, Leiden, The Netherlands. nicole.datson@vicotx.com. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%228900963%22">Molecular neurobiology</searchLink> [Mol Neurobiol] 2025 Oct; Vol. 62 (10), pp. 12768-12790. <i>Date of Electronic Publication: </i>2025 May 31. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: Language Label: Language Group: Lang Data: English – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Humana+Press%22">Humana Press </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>8900963 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1559-1182 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2208937648%22">08937648 </searchLink><i>NLM ISO Abbreviation: </i>Mol Neurobiol <i>Subsets: </i>MEDLINE – Name: PublisherInfo Label: Imprint Name(s) Group: PubInfo Data: <i>Original Publication</i>: Clifton, NJ : Humana Press, c1987- – Name: SubjectMESH Label: MeSH Terms Group: Su Data: <searchLink fieldCode="MM" term="%22Peptides%22">Peptides*</searchLink>/<searchLink fieldCode="MM" term="%22Peptides+analysis%22">analysis</searchLink> <br /><searchLink fieldCode="MM" term="%22Peptides%22">Peptides*</searchLink>/<searchLink fieldCode="MM" term="%22Peptides+genetics%22">genetics</searchLink> <br /><searchLink fieldCode="MM" term="%22Peptides%22">Peptides*</searchLink>/<searchLink fieldCode="MM" term="%22Peptides+metabolism%22">metabolism</searchLink> <br /><searchLink fieldCode="MM" term="%22Mutation%22">Mutation*</searchLink>/<searchLink fieldCode="MM" term="%22Mutation+genetics%22">genetics</searchLink> <br /><searchLink fieldCode="MM" term="%22Mutant+Proteins%22">Mutant Proteins*</searchLink>/<searchLink fieldCode="MM" term="%22Mutant+Proteins+analysis%22">analysis</searchLink> <br /><searchLink fieldCode="MM" term="%22Mutant+Proteins%22">Mutant Proteins*</searchLink>/<searchLink fieldCode="MM" term="%22Mutant+Proteins+metabolism%22">metabolism</searchLink> <br /><searchLink fieldCode="MM" term="%22Blotting%2C+Western%22">Blotting, Western*</searchLink>/<searchLink fieldCode="MM" term="%22Blotting%2C+Western+methods%22">methods</searchLink><br /><searchLink fieldCode="MH" term="%22Immunoassay%22">Immunoassay</searchLink>/<searchLink fieldCode="MH" term="%22Immunoassay+methods%22">methods</searchLink> ; <searchLink fieldCode="MH" term="%22Humans%22">Humans</searchLink> ; <searchLink fieldCode="MH" term="%22Huntingtin+Protein%22">Huntingtin Protein</searchLink> ; <searchLink fieldCode="MH" term="%22Animals%22">Animals</searchLink> – Name: Abstract Label: Abstract Group: Ab Data: Polyglutamine (polyQ) diseases are monogenic fatal neurodegenerative disorders caused by a CAG repeat expansion that is translated into a toxic polyQ tract. There are nine polyQ diseases: Huntington's disease (HD), spinocerebellar ataxias 1, 2, 3, 6, 7 and 17 (SCA1, 2, 3, 6, 7, 17), dentatorubral-pallidoluysian atrophy (DRPLA) and spinal and bulbar muscular atrophy (SBMA). Although no disease-modifying therapies are available, lowering levels of the causative mutant polyQ protein is a promising potential treatment. Preclinically, the efficacy of polyQ protein-lowering compounds is often assessed using time-consuming Western blots (WB), which can produce variable results. Therefore, to improve throughput and accuracy of polyQ protein level quantification, Simple Western (SW) capillary immunoassays were developed. A panel of antibodies was screened for reactivity to the polyQ proteins on SW. The most promising antibodies were selected for further assay development. This resulted in optimised SW immunoassays for huntingtin (HTT), ataxin 1, 2 and 3 (ATXN1, 2, 3), atrophin 1 (ATN1) and androgen receptor (AR). Additionally, size-separation of the wild-type and polyQ-expanded mutant protein isoforms on SW was shown for ATXN1, ATXN3 and ATN1, allowing for their separate quantification. To facilitate size-separation of the larger HTT protein (≥ 348 kDa), a novel caspase 3-based assay was developed to generate N-terminal wild-type and mutant HTT fragments that could be separately quantified on SW in contrast to full-length HTT. In conclusion, SW capillary immunoassays were developed for polyQ proteins to improve preclinical research and aid the development of polyQ-lowering therapies for polyQ diseases.<br /> (© 2025. The Author(s).) – Name: Abstract Label: Competing Interests Group: Ab Data: Declarations. Ethics Approval: Not applicable. Consent to Participate: Not applicable. Consent for Publication: Not applicable. Competing Interests: Financial interest: All authors are employed and paid by VICO Therapeutics B.V. and hold employee stock options. – Name: Ref Label: References Group: RefInfo Data: Neuron. 1997 Aug;19(2):333-44. (PMID: <searchLink fieldCode="PM" term="%229292723%22">9292723)</searchLink><br />Hum Mol Genet. 2002 Nov 1;11(23):2905-17. (PMID: <searchLink fieldCode="PM" term="%2212393802%22">12393802)</searchLink><br />Mov Disord. 2023 Aug;38(8):1428-1442. (PMID: <searchLink fieldCode="PM" term="%2237278528%22">37278528)</searchLink><br />Proc Natl Acad Sci U S A. 2013 Feb 5;110(6):2366-70. (PMID: <searchLink fieldCode="PM" term="%2223341618%22">23341618)</searchLink><br />Annu Rev Pathol. 2019 Jan 24;14:1-27. (PMID: <searchLink fieldCode="PM" term="%2230089230%22">30089230)</searchLink><br />Sci Adv. 2023 Mar 17;9(11):eade2175. (PMID: <searchLink fieldCode="PM" term="%2236921044%22">36921044)</searchLink><br />J Biol Chem. 1999 Mar 26;274(13):8730-6. (PMID: <searchLink fieldCode="PM" term="%2210085113%22">10085113)</searchLink><br />Int Rev Neurobiol. 2011;98:325-72. (PMID: <searchLink fieldCode="PM" term="%2221907094%22">21907094)</searchLink><br />N Engl J Med. 2023 Dec 7;389(23):2203-2205. (PMID: <searchLink fieldCode="PM" term="%2238055260%22">38055260)</searchLink><br />FEBS J. 2010 Dec;277(23):4873-87. (PMID: <searchLink fieldCode="PM" term="%2220977674%22">20977674)</searchLink><br />Mov Disord. 2021 Nov;36(11):2464-2467. (PMID: <searchLink fieldCode="PM" term="%2234783387%22">34783387)</searchLink><br />J Vis Exp. 2018 Feb 27;(132):. (PMID: <searchLink fieldCode="PM" term="%2229553509%22">29553509)</searchLink><br />Int J Mol Sci. 2024 Jun 20;25(12):. (PMID: <searchLink fieldCode="PM" term="%2238928495%22">38928495)</searchLink><br />Electrophoresis. 2009 Jun;30(11):1845-55. (PMID: <searchLink fieldCode="PM" term="%2219517440%22">19517440)</searchLink><br />J Transl Med. 2015 Jun 06;13:182. (PMID: <searchLink fieldCode="PM" term="%2226048678%22">26048678)</searchLink><br />Biotechnol Genet Eng Rev. 2013;29:73-109. (PMID: <searchLink fieldCode="PM" term="%2224568254%22">24568254)</searchLink><br />Molecules. 2018 Oct 08;23(10):. (PMID: <searchLink fieldCode="PM" term="%2230297632%22">30297632)</searchLink><br />Methods Protoc. 2023 Apr 20;6(2):. (PMID: <searchLink fieldCode="PM" term="%2237104025%22">37104025)</searchLink><br />Br J Clin Pharmacol. 2024 Dec;90(12):3242-3251. (PMID: <searchLink fieldCode="PM" term="%2239155237%22">39155237)</searchLink><br />Neurology. 1995 Jan;45(1):143-9. (PMID: <searchLink fieldCode="PM" term="%227824105%22">7824105)</searchLink><br />J Immunol Methods. 2003 Mar 1;274(1-2):1-15. (PMID: <searchLink fieldCode="PM" term="%2212609528%22">12609528)</searchLink><br />J Pathol. 2008 Dec;216(4):387-93. (PMID: <searchLink fieldCode="PM" term="%2218853439%22">18853439)</searchLink><br />Neurol Res Pract. 2019 Jul 03;1:22. (PMID: <searchLink fieldCode="PM" term="%2233324888%22">33324888)</searchLink><br />Hum Mol Genet. 1998 Feb;7(2):171-6. (PMID: <searchLink fieldCode="PM" term="%229425223%22">9425223)</searchLink><br />Biochim Biophys Acta. 2013 May;1829(5):455-68. (PMID: <searchLink fieldCode="PM" term="%2223403288%22">23403288)</searchLink><br />Neurobiol Dis. 2024 Apr;193:106456. (PMID: <searchLink fieldCode="PM" term="%2238423193%22">38423193)</searchLink><br />Nature. 2008 Apr 10;452(7188):713-8. (PMID: <searchLink fieldCode="PM" term="%2218337722%22">18337722)</searchLink><br />Mol Neurodegener. 2015 Apr 28;10:21. (PMID: <searchLink fieldCode="PM" term="%2225928884%22">25928884)</searchLink><br />Genome Med. 2009 Aug 21;1(8):80. (PMID: <searchLink fieldCode="PM" term="%2219725930%22">19725930)</searchLink><br />PLoS One. 2017 Feb 9;12(2):e0171127. (PMID: <searchLink fieldCode="PM" term="%2228182673%22">28182673)</searchLink><br />Proc Natl Acad Sci U S A. 2009 Feb 10;106(6):1760-5. (PMID: <searchLink fieldCode="PM" term="%2219181854%22">19181854)</searchLink><br />Annu Rev Neurosci. 2007;30:575-621. (PMID: <searchLink fieldCode="PM" term="%2217417937%22">17417937)</searchLink><br />Cell. 1996 Nov 1;87(3):493-506. (PMID: <searchLink fieldCode="PM" term="%228898202%22">8898202)</searchLink><br />Database (Oxford). 2023 Aug 18;2023:. (PMID: <searchLink fieldCode="PM" term="%2237599593%22">37599593)</searchLink><br />J Biol Chem. 2019 Jan 11;294(2):644-661. (PMID: <searchLink fieldCode="PM" term="%2230455355%22">30455355)</searchLink><br />Cell Death Dis. 2024 Jun 14;15(6):415. (PMID: <searchLink fieldCode="PM" term="%2238877004%22">38877004)</searchLink><br />Sci Rep. 2021 Jan 26;11(1):2184. (PMID: <searchLink fieldCode="PM" term="%2233500497%22">33500497)</searchLink><br />MAbs. 2018 May/Jun;10(4):539-546. (PMID: <searchLink fieldCode="PM" term="%2229485921%22">29485921)</searchLink><br />Nucleic Acids Res. 2011 Nov 1;39(20):8938-51. (PMID: <searchLink fieldCode="PM" term="%2221795378%22">21795378)</searchLink><br />Elife. 2021 May 13;10:. (PMID: <searchLink fieldCode="PM" term="%2233983118%22">33983118)</searchLink><br />PLoS Genet. 2010 Jul 08;6(7):e1001021. (PMID: <searchLink fieldCode="PM" term="%2220628574%22">20628574)</searchLink><br />Curr Trends Neurol. 2011 Jan 1;5:65-78. (PMID: <searchLink fieldCode="PM" term="%2222180703%22">22180703)</searchLink><br />Hum Mol Genet. 2005 May 15;14(10):1379-92. (PMID: <searchLink fieldCode="PM" term="%2215829505%22">15829505)</searchLink><br />EMBO Mol Med. 2024 Mar;16(3):523-546. (PMID: <searchLink fieldCode="PM" term="%2238374466%22">38374466)</searchLink><br />Brain. 2020 Feb 1;143(2):407-429. (PMID: <searchLink fieldCode="PM" term="%2231738395%22">31738395)</searchLink><br />Electrophoresis. 2021 Feb;42(3):206-218. (PMID: <searchLink fieldCode="PM" term="%2233185281%22">33185281)</searchLink><br />J Clin Invest. 2015 May;125(5):1979-86. (PMID: <searchLink fieldCode="PM" term="%2225844897%22">25844897)</searchLink><br />Hum Mutat. 2002 Sep;20(3):233. (PMID: <searchLink fieldCode="PM" term="%2212204002%22">12204002)</searchLink><br />Front Cell Neurosci. 2018 Sep 19;12:290. (PMID: <searchLink fieldCode="PM" term="%2230283301%22">30283301)</searchLink><br />Mol Med. 2024 Mar 8;30(1):36. (PMID: <searchLink fieldCode="PM" term="%2238459427%22">38459427)</searchLink><br />Mov Disord. 2022 Dec;37(12):2327-2335. (PMID: <searchLink fieldCode="PM" term="%2236161673%22">36161673)</searchLink><br />Neurol Genet. 2017 May 15;3(3):e155. (PMID: <searchLink fieldCode="PM" term="%2228534046%22">28534046)</searchLink><br />Neuron. 2015 Nov 18;88(4):667-77. (PMID: <searchLink fieldCode="PM" term="%2226590344%22">26590344)</searchLink><br />J Biol Chem. 2003 Apr 11;278(15):13047-55. (PMID: <searchLink fieldCode="PM" term="%2212464607%22">12464607)</searchLink><br />Anal Biochem. 2023 Aug 1;674:115198. (PMID: <searchLink fieldCode="PM" term="%2237302777%22">37302777)</searchLink><br />Brain. 2006 Jun;129(Pt 6):1446-55. (PMID: <searchLink fieldCode="PM" term="%2216621916%22">16621916)</searchLink><br />J Biol Chem. 2008 Apr 18;283(16):10745-52. (PMID: <searchLink fieldCode="PM" term="%2218292091%22">18292091)</searchLink><br />J Biol Chem. 2000 Jun 30;275(26):19831-8. (PMID: <searchLink fieldCode="PM" term="%2210770929%22">10770929)</searchLink><br />Hum Mol Genet. 1995 Jun;4(6):1001-5. (PMID: <searchLink fieldCode="PM" term="%227655453%22">7655453)</searchLink><br />J Neurol. 2021 Apr;268(4):1304-1315. (PMID: <searchLink fieldCode="PM" term="%2233106888%22">33106888)</searchLink><br />Ann Neurol. 1996 Apr;39(4):500-6. (PMID: <searchLink fieldCode="PM" term="%228619528%22">8619528)</searchLink><br />Sci Signal. 2015 Apr 07;8(371):rs2. (PMID: <searchLink fieldCode="PM" term="%2225852189%22">25852189)</searchLink><br />Anal Biochem. 2020 Mar 15;593:113608. (PMID: <searchLink fieldCode="PM" term="%2232007473%22">32007473)</searchLink><br />Neurology. 1997 Nov;49(5):1238-43. (PMID: <searchLink fieldCode="PM" term="%229371900%22">9371900)</searchLink><br />ACS Chem Neurosci. 2018 Jun 20;9(6):1399-1408. (PMID: <searchLink fieldCode="PM" term="%2229506378%22">29506378)</searchLink><br />Mov Disord. 2021 Nov;36(11):2675-2681. (PMID: <searchLink fieldCode="PM" term="%2234397117%22">34397117)</searchLink><br />Eur J Hum Genet. 2015 Nov;23(11):1505-12. (PMID: <searchLink fieldCode="PM" term="%2225735478%22">25735478)</searchLink><br />Nucleic Acids Res. 2014 Jun;42(11):6787-810. (PMID: <searchLink fieldCode="PM" term="%2224848018%22">24848018)</searchLink><br />Nature. 2015 Feb 5;518(7537):27-9. (PMID: <searchLink fieldCode="PM" term="%2225652980%22">25652980)</searchLink><br />Neurology. 2023 Jan 3;100(1):e84-e93. (PMID: <searchLink fieldCode="PM" term="%2236180235%22">36180235)</searchLink><br />Adv Exp Med Biol. 2018;1049:219-231. (PMID: <searchLink fieldCode="PM" term="%2229427105%22">29427105)</searchLink><br />J Biol Chem. 1998 Apr 10;273(15):9158-67. (PMID: <searchLink fieldCode="PM" term="%229535906%22">9535906)</searchLink><br />Biomed Res Int. 2019 Jan 21;2019:5214821. (PMID: <searchLink fieldCode="PM" term="%2230800670%22">30800670)</searchLink><br />Int J Clin Exp Pathol. 2011 Apr;4(4):378-84. (PMID: <searchLink fieldCode="PM" term="%2221577324%22">21577324)</searchLink><br />Nat Commun. 2019 Sep 19;10(1):4262. (PMID: <searchLink fieldCode="PM" term="%2231537808%22">31537808)</searchLink><br />Neurotherapeutics. 2019 Oct;16(4):1050-1073. (PMID: <searchLink fieldCode="PM" term="%2231435879%22">31435879)</searchLink><br />Neuroepidemiology. 2014;42(3):174-83. (PMID: <searchLink fieldCode="PM" term="%2224603320%22">24603320)</searchLink><br />Int J Mol Sci. 2021 Apr 19;22(8):. (PMID: <searchLink fieldCode="PM" term="%2233921915%22">33921915)</searchLink><br />Mol Ther Nucleic Acids. 2019 Sep 6;17:601-614. (PMID: <searchLink fieldCode="PM" term="%2231394429%22">31394429)</searchLink><br />PLoS One. 2012;7(9):e44785. (PMID: <searchLink fieldCode="PM" term="%2222970306%22">22970306)</searchLink><br />Trends Neurosci. 2001 Mar;24(3):182-8. (PMID: <searchLink fieldCode="PM" term="%2211182459%22">11182459)</searchLink><br />ILAR J. 2007;48(4):356-73. (PMID: <searchLink fieldCode="PM" term="%2217712222%22">17712222)</searchLink><br />Cell Death Dis. 2013 Aug 01;4:e752. (PMID: <searchLink fieldCode="PM" term="%2223907466%22">23907466)</searchLink><br />Am J Med Genet B Neuropsychiatr Genet. 2010 Mar 5;153B(2):397-408. (PMID: <searchLink fieldCode="PM" term="%2219548255%22">19548255)</searchLink><br />Neuroscientist. 2011 Oct;17(5):475-92. (PMID: <searchLink fieldCode="PM" term="%2221311053%22">21311053)</searchLink><br />Am J Hum Genet. 2024 May 2;111(5):913-926. (PMID: <searchLink fieldCode="PM" term="%2238626762%22">38626762)</searchLink><br />Sci Adv. 2021 Aug 20;7(34):. (PMID: <searchLink fieldCode="PM" term="%2234417184%22">34417184)</searchLink><br />Brain Pathol. 2016 Nov;26(6):779-786. (PMID: <searchLink fieldCode="PM" term="%2227529325%22">27529325)</searchLink><br />J Mol Biol. 2020 Dec 4;432(24):166699. (PMID: <searchLink fieldCode="PM" term="%2233157084%22">33157084)</searchLink> – Name: SubjectMinor Label: Contributed Indexing Group: Data: <i>Keywords: </i>Assay development; Capillary immunoassay; Huntington’s disease; Polyglutamine diseases; Protein quantification; Spinocerebellar ataxias – Name: NumberCAS Label: Substance Nomenclature Group: ID Data: 26700-71-0 (polyglutamine)<br />0 (Peptides)<br />0 (Mutant Proteins)<br />0 (Huntingtin Protein) – Name: DateEntry Label: Entry Date(s) Group: Date Data: <i>Date Created: </i>20250531 <i>Date Completed: </i>20250916 <i>Latest Revision: </i>20250916 – Name: DateUpdate Label: Update Code Group: Date Data: 20260130 – Name: PubmedCentralID Label: PubMed Central ID Group: ID Data: PMC12433360 – Name: DOI Label: DOI Group: ID Data: 10.1007/s12035-025-05089-9 – Name: AN Label: PMID Group: ID Data: 40450087 |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=cmedm&AN=40450087 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1007/s12035-025-05089-9 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 12768 Subjects: – SubjectFull: Immunoassay methods Type: general – SubjectFull: Humans Type: general – SubjectFull: Huntingtin Protein Type: general – SubjectFull: Animals Type: general – SubjectFull: Peptides analysis Type: general – SubjectFull: Peptides genetics Type: general – SubjectFull: Peptides metabolism Type: general – SubjectFull: Mutation genetics Type: general – SubjectFull: Mutant Proteins analysis Type: general – SubjectFull: Mutant Proteins metabolism Type: general – SubjectFull: Blotting, Western methods Type: general Titles: – TitleFull: Accurate Quantification of Mutant and Wild-Type polyQ Proteins Using Simple Western Capillary Immunoassays. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Röttgering B – PersonEntity: Name: NameFull: Testerink J – PersonEntity: Name: NameFull: Weij R – PersonEntity: Name: NameFull: Beekman C – PersonEntity: Name: NameFull: Datson N IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 10 Text: 2025 Oct Type: published Y: 2025 Identifiers: – Type: issn-electronic Value: 1559-1182 Numbering: – Type: volume Value: 62 – Type: issue Value: 10 Titles: – TitleFull: Molecular neurobiology Type: main |
| ResultId | 1 |